Why Choose PiaSky® (crovalimab) for PNH

Put your patients in control of their PNH treatment: a C5 inhibitor in a convenient subcutaneous injection1-3*

 

PiaSky® is the latest addition to the standard of PNH care.2,4

Product image

PiaSky® (crovalimab) is the preferred choice for people with PNH

Across arms, the top reasons for PiaSky® preference included8:

PiaSky® enhances standard of care with innovative SMART-Ig recycling technology

PNH patients currently have a significant treatment burden11

It’s time to give PNH patients their lives back

PiaSky® is available for C5i-naïve and C5i-experienced patients, with consistent efficacy and safety among both patient populations

*Patients starting PiaSky® will receive an initial weight-based loading dose through IV infusion, administered by their healthcare provider. Four subsequent loading doses are then given weekly by subcutaneous injection. Weight-based maintenance dosing is then administered once every 4 weeks subcutaneously. Patients may self-inject after receiving training from their healthcare provider.2
†Patients were assessed after 17 weeks of crovalimab, patients randomized to eculizumab who switched to PiaSky® in the extension period (n=38), only patients with available data (having completed the questionnaire) were included in the calculations of percentages. Questionnaire completion rate was 83%.8
‡Treatment preference among patients in COMMODORE 1 and 2 who were randomized to receive eculizumab (arm B) and switched to PiaSky® in the extension period.
§In COMMODORE 1, a non-randomized arm including patients previously treated with ravulizumab was not included in the randomized arm, patients were assessed after 17 weeks of crovalimab, patients who switched from ravulizumab to PiaSky® (n=15), only patients with available data (having completed the questionnaire) were included in the calculations of percentages. Questionnaire completion rate was 88%.9
PiaSky® treatment begins with a single IV weight-based loading dose administered in the clinic.
C5 = complement protein 5; IV=intravenous; IVH = intravascular hemolysis; PNH = paroxysmal nocturnal hemoglobinuria; SC = subcutaneous; SNP = single nucleotide polymorphism; TICR = transient immune complex reactions; wt = wildtype.
References
  1. Röth A, et al. Blood. 2020.
  2. PiaSky® (crovalimab) 170mg/mL solution for injection Summary of Product Characteristics. F-Hoffmann-La Roche; 2024.
  3. Overton P, et al. Patients Prefer Adherence. 2021;15:811–834.
  4. Bektas M, et al. J Manag Care Spec Pharm. 2020;26:S14–S20.
  5. Scheinberg P, et al. Am J Hematol. 2024;99:1757–1767.
  6. Röth A, et al. Am J Hematol. 2024;99:1768–1777.
  7. Bittner B, et al. BioDrugs. 2018;32:425–440.
  8. Kulasekararaj A, et al. EHA 2024; poster presentation [poster P839].
  9. Scheinberg P, et al. ASH 2024; poster presentation [abs p4078].
  10. Sampei Z, et al. Int J Mol Sci. 2024;25:11679.
  11. Ueda Y, et al. Ann Hematol. 2025;1–10.
  12. Weiss DJ, et al. Nat Med. 2020;26:1835–1838.
  13. Hirth W, et al. ISPOR 2024; poster presentation [poster OP7].
  14. Ultomiris™ (ravulizumab-cvwz) Prescribing Information. Boston MA: Alexion Pharmaceuticals, Inc; 2024.
  15. Soliris® (eculizumab) Prescribing information. Boston, MA: Alexion Pharmaceuticals, Inc; 2024.
  16. Heald A, et al. Int J Clin Pract. 2021;75:e14341.
  17. Peffault de Latour R, et al. Semin Hematol. 2022;59:38–46.
  18. Shah N, et al. Paroxysmal Nocturnal Hemoglobinuria. Available at: https://www.ncbi.nlm.nih.gov/books/NBK562292/#:~:text=Epidemiology,to%2099%20years.%5B2%5D. Accessed July 2025.
  19. Arnold LM, et al. Blood. 2008;112:4671.
  20. Bril V, et al. J Comp Eff Res. 2024;13:e230171.
  21. Teriou L, et al. EHA 2023; poster presentation [abs P783].
  22. Araten D, et al. Blood. 2024;144:3706–3707.
  23. Food and Drug Administration. PiaSky (crovalimab-akkz) new drug application integrated review. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761388Orig1s000IntegratedR.pdf. Accessed July 2025.